JP2020512820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512820A5 JP2020512820A5 JP2019554816A JP2019554816A JP2020512820A5 JP 2020512820 A5 JP2020512820 A5 JP 2020512820A5 JP 2019554816 A JP2019554816 A JP 2019554816A JP 2019554816 A JP2019554816 A JP 2019554816A JP 2020512820 A5 JP2020512820 A5 JP 2020512820A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human igm
- constant region
- modified human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062508A JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483087P | 2017-04-07 | 2017-04-07 | |
| US62/483,087 | 2017-04-07 | ||
| PCT/US2018/026474 WO2018187702A2 (en) | 2017-04-07 | 2018-04-06 | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062508A Division JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512820A JP2020512820A (ja) | 2020-04-30 |
| JP2020512820A5 true JP2020512820A5 (enExample) | 2021-10-07 |
Family
ID=63713537
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554816A Withdrawn JP2020512820A (ja) | 2017-04-07 | 2018-04-06 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2023062508A Pending JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A Pending JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062508A Pending JP2023085503A (ja) | 2017-04-07 | 2023-04-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
| JP2024175523A Pending JP2024177479A (ja) | 2017-04-07 | 2024-10-07 | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11401337B2 (enExample) |
| EP (1) | EP3607091A4 (enExample) |
| JP (3) | JP2020512820A (enExample) |
| KR (1) | KR102696143B1 (enExample) |
| CN (1) | CN110536900B (enExample) |
| AU (1) | AU2018248336B2 (enExample) |
| CA (1) | CA3055790A1 (enExample) |
| IL (1) | IL268901B2 (enExample) |
| MX (1) | MX2019011986A (enExample) |
| SG (1) | SG11201908051RA (enExample) |
| WO (1) | WO2018187702A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| CA3113268A1 (en) * | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
| EP4013792A4 (en) | 2019-08-15 | 2023-10-04 | IGM Biosciences Inc. | IMMUNO-STIMULATING MULTIMER BINDING MOLECULES |
| US20220372142A1 (en) * | 2019-09-19 | 2022-11-24 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| CA3240270A1 (en) * | 2022-02-03 | 2023-08-10 | Keyu LI | Anti-cd38 binding molecules and uses thereof |
| CA3245061A1 (en) | 2022-04-07 | 2023-10-12 | Repertoire Immune Medicines Inc | T-CELL RECEIVER MULTIMERS AND THEIR USES |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| RU2377254C2 (ru) | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| JP2008519030A (ja) | 2004-11-05 | 2008-06-05 | パリンゲン インコーポレーテッド | 抗体で誘導される細胞膜損傷 |
| US20120316071A1 (en) * | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| WO2013049254A1 (en) * | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| MX363819B (es) | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| US9416496B2 (en) * | 2013-10-16 | 2016-08-16 | Georgia-Pacific Consumer Products Lp | Method for reducing the bulk and increasing the density of a tissue product |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| WO2015129651A1 (ja) * | 2014-02-25 | 2015-09-03 | 富士レビオ株式会社 | 改変単量体ＩｇＭ |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| WO2017053469A2 (en) * | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| CN105441455B (zh) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| WO2018017761A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| AU2017299610B2 (en) | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
| CA3030647A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| CN109561681A (zh) | 2016-07-20 | 2019-04-02 | Igm生物科学股份有限公司 | 多聚gitr结合分子及其用途 |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111757941A (zh) | 2018-02-26 | 2020-10-09 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| CA3113268A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
-
2018
- 2018-04-06 US US16/500,292 patent/US11401337B2/en active Active
- 2018-04-06 JP JP2019554816A patent/JP2020512820A/ja not_active Withdrawn
- 2018-04-06 EP EP18781914.9A patent/EP3607091A4/en active Pending
- 2018-04-06 SG SG11201908051RA patent/SG11201908051RA/en unknown
- 2018-04-06 MX MX2019011986A patent/MX2019011986A/es unknown
- 2018-04-06 KR KR1020197030684A patent/KR102696143B1/ko active Active
- 2018-04-06 CA CA3055790A patent/CA3055790A1/en active Pending
- 2018-04-06 CN CN201880022469.1A patent/CN110536900B/zh active Active
- 2018-04-06 WO PCT/US2018/026474 patent/WO2018187702A2/en not_active Ceased
- 2018-04-06 AU AU2018248336A patent/AU2018248336B2/en active Active
-
2019
- 2019-08-25 IL IL268901A patent/IL268901B2/en unknown
-
2022
- 2022-06-10 US US17/806,339 patent/US20220340676A1/en not_active Abandoned
-
2023
- 2023-04-07 JP JP2023062508A patent/JP2023085503A/ja active Pending
-
2024
- 2024-10-07 JP JP2024175523A patent/JP2024177479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512820A5 (enExample) | ||
| JP2020503885A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2019528077A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| JP2018519296A5 (enExample) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2024177479A (ja) | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 | |
| JP2017526350A5 (enExample) | ||
| JP5142265B2 (ja) | 抗モータリン抗体のパラトープ及びエピトープ | |
| CN113195516A (zh) | 由特异性结合物识别的表位标签 | |
| CA2977350A1 (en) | Bivalent antibody directed against nkg2d and tumor associated antigens | |
| AR101936A1 (es) | Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas | |
| HRP20251051T1 (hr) | Anti-cd3 antitijelo i molekula koja sadrži navedeno antitijelo | |
| JP2018507254A5 (enExample) | ||
| JP2021520209A (ja) | 癌患者における腫瘍抗原を検出するための診断アッセイ | |
| Mutsvunguma et al. | Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes | |
| PH12018502293B1 (en) | Humanized anti-basigin antibodies and the use thereof | |
| JP2018504903A5 (enExample) | ||
| US11505614B2 (en) | Antibodies binding to soluble BCMA | |
| JP2017509323A5 (enExample) | ||
| JP2021519588A (ja) | がん患者における腫瘍抗原を検出するための診断アッセイ | |
| WO2023060137A3 (en) | Methods and compositions comprising b7-h3 binding polypeptides | |
| KR20200019946A (ko) | 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용 |